Unlocking the Potential of DNALI1: A Drug Target and Biomarker for Inner Dynein Arm in Inner Ear Disorders

Target Name: DNALI1

NCBI ID: G7802

DNALI1

Unlocking the Potential of DNALI1: A Drug Target and Biomarker for Inner Dynein Arm in Inner Ear Disorders

Introduction

The inner ear is a critical sense organ responsible for the sensation of balance and spatial orientation. Inner dynein arm (IDA) is a protein that plays a crucial role in the function of the inner ear. It is composed of two subunits, IDA1 and IDA2 , which are involved in the regulation of the movement of fluid through the ear's tiny channels. The IDA is also known as the flagellum because it is responsible for pushing the flow of fluid in the inner ear. However, IDA dysfunction can lead to inner ear diseases, such as otolithiasis, benign positional vertigo, tinnitus, etc. Therefore, studying IDA and its related molecular mechanisms is a potential drug target for the treatment of these diseases. This article will discuss the potential of IDA as a drug target or biomarker.

IDA and its functions

IDA is a transmembrane protein widely expressed in humans and other organisms. Its main function is to regulate the flow of fluid in the inner ear through two main domains: the D1 and D2 domains. The D1 domain includes a short tail region that is capable of binding ions in liquids. The D2 domain includes a long tail region that is capable of binding proteins in liquids. The interaction between the two domains allows IDA to recognize and bind to proteins in the liquid, thereby regulating its flow.

IDA disease risk

IDA plays an important role in diseases such as otolithiasis, benign positional vertigo, and tinnitus. In these diseases, dysfunction of the IDA causes abnormal flow of fluid in the inner ear, resulting in inner ear pressure imbalance. IDA has been found to be useful in some treatments for otolithiasis and other conditions. For example, by inhibiting IDA function, the pressure in the inner ear can be reduced, thereby improving the patient's symptoms.

IDA drug targets

IDA is a protein and therefore can be a drug target. Scientists have discovered a variety of molecular mechanisms related to IDA that help understand the function of IDA. These molecular mechanisms include:

1. IDA interacts with fluids: IDA regulates the flow of liquids by binding to ions and proteins in them. Therefore, by inhibiting IDA from interacting with fluid, inner ear pressure can be reduced, thereby improving patients' symptoms.

2. Interaction between IDA and nerve cells: IDA plays an important role in nerve cells. Research shows that IDA can bind to surface receptors on nerve cells, thereby affecting the signal transmission of nerve cells. By inhibiting the interaction between IDA and nerve cells, the response of nerve cells can be reduced, thereby improving the patient's symptoms.

3. Interaction between IDA and molecules: IDA can also interact with molecules, such as binding to glutamate receptors. These interactions help understand IDA's function in the nervous system.

Biomarkers of IDA

IDA's potential role in disease diagnosis and treatment also makes it a biomarker. For example, some studies have shown that measuring IDA levels can predict a patient's response to certain treatments for otolithiasis. In addition, studies have shown that measuring IDA levels can predict a patient's response to drugs. These studies bring great potential for IDA as a biomarker.

in conclusion

IDA is a protein that plays an important role in otolithiasis, benign positional vertigo, tinnitus and other diseases. IDA has become a research focus due to its potential as a drug target or biomarker. Future research will focus on the molecular mechanisms of IDA and how IDA interacts with other molecules. These studies will help develop new treatments for otolithiasis and other diseases.

Protein Name: Dynein Axonemal Light Intermediate Chain 1

Functions: May play a dynamic role in flagellar motility

The "DNALI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNALI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets